Group One Trading’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-250,200
| Closed | -$6.03M | – | 8485 |
|
|
2023
Q1 | $6.03M | Buy |
250,200
+42,500
| +20% | +$533K | 0.02% | 743 |
|
|
2022
Q4 | $2.2M | Buy |
207,700
+147,900
| +247% | +$1.19M | 0.01% | 1750 |
|
|
2022
Q3 | $269K | Sell |
59,800
-3,000
| -5% | -$13.7K | ﹤0.01% | 3858 |
|
|
2022
Q2 | $251K | Sell |
62,800
-350,100
| -85% | -$1.66M | ﹤0.01% | 4079 |
|
|
2022
Q1 | $3.02M | Buy |
412,900
+164,500
| +66% | +$984K | ﹤0.01% | 1984 |
|
|
2021
Q4 | $1.4M | Buy |
248,400
+156,400
| +170% | +$993K | ﹤0.01% | 2984 |
|
|
2021
Q3 | $589K | Sell |
92,000
-348,400
| -79% | -$2.24M | ﹤0.01% | 4004 |
|
|
2021
Q2 | $3.71M | Sell |
440,400
-23,200
| -5% | -$187K | ﹤0.01% | 1990 |
|
|
2021
Q1 | $4.87M | Buy |
463,600
+452,000
| +3,897% | +$6.36M | 0.01% | 1543 |
|
|
2020
Q4 | $197K | Sell |
11,600
-77,200
| -87% | -$1.16M | ﹤0.01% | 4067 |
|
|
2020
Q3 | $1.14M | Sell |
88,800
-58,300
| -40% | -$736K | ﹤0.01% | 2073 |
|
|
2020
Q2 | $2.08M | Buy |
147,100
+76,300
| +108% | +$963K | 0.01% | 1447 |
|
|
2020
Q1 | $651K | Buy |
70,800
+14,900
| +27% | +$192K | 0.01% | 1859 |
|
|
2019
Q4 | $833K | Buy |
55,900
+45,900
| +459% | +$409K | 0.01% | 2040 |
|
|
2019
Q3 | $68K | Buy |
+10,000
| New | +$101K | ﹤0.01% | 3819 |
|
Other funds holding PRVB
Group One Trading's PRVB Position: Q2 2023 in Review
Group One Trading sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 24,190 shares — an estimated $583K sold.
Group One Trading first reported a position in PRVB in Q3 2019 and held it in 13 quarters. The position peaked at $1.99M in Q4 2022. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Group One Trading reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Group One Trading sold 24,190 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $583K.
- Group One Trading first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 13 quarters.
- Group One Trading's Provention Bio, Inc. Common Stock position peaked at $1.99M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Group One Trading's 13F filing for Q2 2023, filed 9 Aug 2023.